生存获益-话题@MedSci - 梅斯（MedSci）

#生存获益#

63篇内容 | 2564人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2006976, encodeId=db7e20069e691, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, objectType=article, longId=728900, objectId=2d14e28900af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d14e28900af, replyNumber=0, likeNumber=101, createdTime=2022-12-04, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d14e28900af, moduleTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2d14e28900af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006977, encodeId=139720069e716, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, objectType=article, longId=735666, objectId=d837e3566673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d837e3566673, replyNumber=0, likeNumber=106, createdTime=2022-12-26, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d837e3566673, moduleTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d837e3566673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006975, encodeId=f08420069e5f3, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=ASCO 2022 | 慢性淋巴细胞白血病一线疗法：Calquence联合奥妥珠单抗持续生存获益：5年生存率达到90%！, objectType=article, longId=728833, objectId=026ae2883362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=026ae2883362, replyNumber=0, likeNumber=148, createdTime=2022-12-30, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=026ae2883362, moduleTitle=ASCO 2022 | 慢性淋巴细胞白血病一线疗法：Calquence联合奥妥珠单抗持续生存获益：5年生存率达到90%！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=026ae2883362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006974, encodeId=1a0a20069e4d9, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, objectType=article, longId=726547, objectId=916ae26547dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=916ae26547dc, replyNumber=0, likeNumber=113, createdTime=2023-03-04, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=916ae26547dc, moduleTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=916ae26547dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006973, encodeId=7a0620069e3b0, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, objectType=article, longId=301447, objectId=d0c230144eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c230144eb9, replyNumber=0, likeNumber=129, createdTime=2022-06-30, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c230144eb9, moduleTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d0c230144eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006970, encodeId=11e620069e019, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益, objectType=article, longId=218467, objectId=821a21846eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=821a21846eea, replyNumber=0, likeNumber=229, createdTime=2022-07-01, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=821a21846eea, moduleTitle=国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=821a21846eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006967, encodeId=b08b200696e0b, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, objectType=article, longId=213493, objectId=fdd621349391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd621349391, replyNumber=0, likeNumber=120, createdTime=2022-03-31, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd621349391, moduleTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fdd621349391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006971, encodeId=819320069e1ff, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益, objectType=article, longId=219361, objectId=8ba3219361e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ba3219361e1, replyNumber=0, likeNumber=125, createdTime=2022-07-31, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ba3219361e1, moduleTitle=N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8ba3219361e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006972, encodeId=b3ac20069e2b9, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益, objectType=article, longId=220044, objectId=e7ea220044a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7ea220044a6, replyNumber=0, likeNumber=127, createdTime=2022-02-17, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7ea220044a6, moduleTitle=NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e7ea220044a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006963, encodeId=c773200696386, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=欧狄沃（纳武利尤单抗）联合化疗及欧狄沃联合伊匹木单抗治疗晚期不可切除或转移性食管鳞癌患者均可带来显著生存获益, objectType=article, longId=209794, objectId=fb68209e9495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb68209e9495, replyNumber=0, likeNumber=122, createdTime=2021-08-15, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb68209e9495, moduleTitle=欧狄沃（纳武利尤单抗）联合化疗及欧狄沃联合伊匹木单抗治疗晚期不可切除或转移性食管鳞癌患者均可带来显著生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb68209e9495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006969, encodeId=b5582006969c8, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据, objectType=article, longId=217868, objectId=7f5c21e868c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f5c21e868c1, replyNumber=0, likeNumber=115, createdTime=2022-07-14, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f5c21e868c1, moduleTitle=Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7f5c21e868c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006965, encodeId=c8212006965de, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=JCO: 对错配修复基因缺陷的人群进行监测管理可带来生存获益, objectType=article, longId=211022, objectId=e5e4211022c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e4211022c9, replyNumber=0, likeNumber=113, createdTime=2021-05-26, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e4211022c9, moduleTitle=JCO: 对错配修复基因缺陷的人群进行监测管理可带来生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e5e4211022c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006964, encodeId=d14420069646f, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！, objectType=article, longId=210515, objectId=4d42210515e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d42210515e4, replyNumber=0, likeNumber=104, createdTime=2022-02-03, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d42210515e4, moduleTitle=J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4d42210515e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006968, encodeId=00c3200696871, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, objectType=article, longId=214268, objectId=9fbc2142681c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fbc2142681c, replyNumber=0, likeNumber=95, createdTime=2021-08-18, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fbc2142681c, moduleTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9fbc2142681c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006955, encodeId=448f20069551b, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, objectType=article, longId=199161, objectId=739d19916169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739d19916169, replyNumber=0, likeNumber=125, createdTime=2020-09-07, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739d19916169, moduleTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=739d19916169)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006957, encodeId=91ce200695ea7, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=真实世界研究发布，全球**肿瘤电场治疗为中国患者带来生存获益, objectType=article, longId=200826, objectId=8437200826ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8437200826ed, replyNumber=0, likeNumber=92, createdTime=2021-06-18, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8437200826ed, moduleTitle=真实世界研究发布，全球**肿瘤电场治疗为中国患者带来生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8437200826ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006966, encodeId=0581200696644, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=Gut:机器学习模式鉴别胃癌紫杉醇生存获益的基因集：来自III期随机临床试验SAMIT的数据分析, objectType=article, longId=211326, objectId=86e5211326cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86e5211326cf, replyNumber=0, likeNumber=0, createdTime=2021-12-26, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86e5211326cf, moduleTitle=Gut:机器学习模式鉴别胃癌紫杉醇生存获益的基因集：来自III期随机临床试验SAMIT的数据分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=86e5211326cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006960, encodeId=650b2006960a3, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=JCO：特瑞普利单抗治疗鼻咽癌患者带来更长生存获益, objectType=article, longId=206306, objectId=4f9e2063068a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f9e2063068a, replyNumber=0, likeNumber=285, createdTime=2021-03-01, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f9e2063068a, moduleTitle=JCO：特瑞普利单抗治疗鼻咽癌患者带来更长生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4f9e2063068a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006961, encodeId=423b2006961d2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=健康生活方式可增寿6年以上，不吸烟具有很大的生存获益, objectType=article, longId=206903, objectId=b52220690364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52220690364, replyNumber=0, likeNumber=203, createdTime=2021-12-22, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52220690364, moduleTitle=健康生活方式可增寿6年以上，不吸烟具有很大的生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b52220690364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2006962, encodeId=ee5d200696265, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, objectTitle=全球鼻咽癌免疫疗法获批，本土新药特瑞普利单抗为患者带来更长生存获益, objectType=article, longId=207407, objectId=f26f20e4076d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26f20e4076d, replyNumber=0, likeNumber=121, createdTime=2021-06-21, rootId=0, userName=ms8538335253054589, userId=8e712500159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26f20e4076d, moduleTitle=全球鼻咽癌免疫疗法获批，本土新药特瑞普利单抗为患者带来更长生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f26f20e4076d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存获益

2020-05-29

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较

2022-12-04

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递

2022-12-26

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

ASCO 2022 | 慢性淋巴细胞白血病一线疗法：Calquence联合奥妥珠单抗持续生存获益：5年生存率达到90%！

2022-12-30

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！

2023-03-04

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益

2022-06-30

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益

2022-07-01

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益

2022-03-31

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益

2022-07-31

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益

2022-02-17

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

欧狄沃（纳武利尤单抗）联合化疗及欧狄沃联合伊匹木单抗治疗晚期不可切除或转移性食管鳞癌患者均可带来显著生存获益

2021-08-15

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据

2022-07-14

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

JCO: 对错配修复基因缺陷的人群进行监测管理可带来生存获益

2021-05-26

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！

2022-02-03

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究

2021-08-18

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验

2020-09-07

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

真实世界研究发布，全球**肿瘤电场治疗为中国患者带来生存获益

2021-06-18

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

Gut:机器学习模式鉴别胃癌紫杉醇生存获益的基因集：来自III期随机临床试验SAMIT的数据分析

2021-12-26

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

JCO：特瑞普利单抗治疗鼻咽癌患者带来更长生存获益

2021-03-01

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

健康生活方式可增寿6年以上，不吸烟具有很大的生存获益

2021-12-22

ms8538335253054589 (审核中...)

前往app查看评论内容

#生存获益#

全球鼻咽癌免疫疗法获批，本土新药特瑞普利单抗为患者带来更长生存获益

2021-06-21

科室
- - 订阅+
  - 更多科室
工具
服务